HGF, hepatocyte growth factor, 3082

N. diseases: 671; N. variants: 22
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 AlteredExpression disease BEFREE Here, we show that HGF is upregulated while microRNA-101-3p is significantly downregulated in the tumor tissues of HCC. 30929159 2020
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE The effects of ERK activation by hepatocyte growth factor (HGF) on eight HCC cell lines were further examined. 31702093 2020
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE Our results suggest IL-6 and HGF may be the key communication molecules for the interaction between LCSLCs and HSCs, and BrMC and chrysin could block these effects and be the novel therapeutic candidates for HCC management. 30866863 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE At weeks 12 and 16 post-induction, effects were compared on HCC nodule formation, microvessel density, and macrophage infiltration, and levels of paraneoplastic protein expression of tumor necrosis factor (TNF)-α, p38 mitogen-activated protein kinase (p38), phosphorylated p38 (p-p38), nuclear factor (NF)-κB, interleukin (IL)-10, hepatocyte growth factor (HGF), transforming growth factor (TGF)-β1 and vascular endothelial growth factor (VEGF). 31807025 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE We analyzed whether AP-2 complex subunit mu (AP2M1) expression could be a new prognostic marker for HCC based on the roles of AP2M1 in influencing hepatocyte growth factor (HGF) promoter regulation and hepatitis C virus (HCV) assembly. 30260026 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE Fibroblast growth factor (FGF), vascular endothelial growth factor, and hepatocyte growth factor play a critical role in the pathogenesis of hepatocellular carcinoma (HCC). 30952770 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 AlteredExpression disease BEFREE Sorafenib resistance is one of the major obstacles towards achieving a better outcome in patients with advanced hepatocellular carcinoma (HCC), in which aberrant activation of the hepatocyte growth factor (HGF)/mesenchymal-epithelial transition pathway is frequently observed. 30761258 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE Our results provide new insights into the mechanisms of sorafenib resistance in HCC and rationale for developing new trials by combining sorafenib with a potent HGF inhibitor such as cabozantinib to improve the first line systemic therapeutic efficacy. 31130723 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE Identification of a peptide that can block HGF/c-Met signaling provides new insight into the mechanism of HCC and future clinical treatments. 31441380 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE HGF modulated biological status in autophagic survival or proliferation of heat-treated residual HCC through HGF/c-Met/ERK signaling and downstream components of ATG5/Beclin1 or cyclinD1. 30701994 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE <b>Abbreviations:</b> ALDO: aldolase, fructose-bisphosphate; CQ: chloroquine; DLAT/PDCE2: dihydrolipoamide S-acetyltransferase; EMT: epithelial-mesenchymal transition; ENO: enolase; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GLS/GLS1: glutaminase; GLUL/GS: glutamine-ammonia ligase; GPI/PGI: glucose-6-phosphate isomerase; HCC: hepatocellular carcinoma; HGF: hepatocyte growth factor; HK: hexokinase; LDH: lactate dehydrogenase; LIHC: liver hepatocellular carcinoma; LIR: LC3-interacting region; PDH: pyruvate dehydrogenase; PDHA1: pyruvate dehydrogenase E1 alpha 1 subunit; PDHX: pyruvate dehydrogenase complex component X; PFK: phosphofructokinase; PK: pyruvate kinase; RTK: receptor tyrosine kinase; TCGA: The Cancer Genome Atlas. 30786811 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE The one-armed anti-c-Met antibody blocked the hepatocyte growth factor (HGF)/c-Met interaction and the subsequent signal transduction, including phosphorylation of c-Met, Grb2-associated binding protein 1(Gab-1), extracellular regulated protein kinases 1/2(Erk1/2), and Akt, also referred to as protein kinase B (PKB) in HCC cell line HepG2. 31849449 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE In the present study, we investigated the effect of S1P on the hepatocyte growth factor (HGF)-induced migration of human HCC-derived HuH7 cells, and the involvement of each S1PR. 30543684 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE Available treatments against HCC based upon HGF/c-Met inhibition can increase patient lifespan, but do not reach the expected therapeutic benefits. 30197476 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 AlteredExpression disease BEFREE In clinical specimens of human HCC (<i>n</i> = 339), HGF and KRT19 protein expression correlated with CAF levels. 29363547 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE MicroRNA-449a suppresses hepatocellular carcinoma cell growth via G1 phase arrest and the HGF/MET c-Met pathway. 30108016 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE The aim of this study was to investigate the diagnostic sensitivity and specificity of protein induced by vitamin K absence or antagonist-II (PIVKAII), Glypican-3 (GP3), Cystatin B (CSTB), squamous cell carcinoma antigen 1 (SCCA1) and hepatocyte growth factor (HGF) as potential tumour markers for HCC in patients with alcoholic liver cirrhosis (ALC) using imaging techniques (MSCT and MRI) as reference standards. 28766361 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE This new model including serum FGF and HGF showed good performance in predicting the response to sorafenib and survival in patients with advanced HCC. 29558905 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE Heat-stress induced rapid MET and EGFR phosphorylation that is distinct from HGF or EGF in HCC cells and thermal ablation induced MET but not EGFR phosphorylation at the HCC tumour ablation margin. 28954551 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE Stable derivatives of mouse (Hepa1-6) and human (hep3B, HepG2) HCC cell lines expressing SOCS1 or control vector were evaluated for their ability to migrate towards hepatocyte growth factor (HGF) in the transwell migration assay, invade extracellular matrix in response to HGF stimulation in a 3-D invasion assay by confocal microscopy, and to undergo anchorage-independent proliferation in semisolid agar. 29085209 2017
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 AlteredExpression disease BEFREE Compared with adjacent normal tissues, the protein and mRNA expressions of HGF were reduced in HCC tissues, but the protein and mRNA expressions of c-Met and MVD were increased. 28243120 2017
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE Among the metastatic factors in the tumor microenvironment, hepatocyte growth factor (HGF) has been well known to play critical roles in tumor progression, including HCC. 28587113 2017
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 AlteredExpression disease BEFREE Herein, we report that resveratrol has a profound antitumor effect on human hepatocellular carcinoma (HCC) cells by down-regulation of the HGF-c-Met signaling pathway. 28075467 2017
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE Our previous studies found that the mRNA expression level of GnT-III decreased in a hepatocyte growth factor (HGF)-induced hepatocellular carcinoma (HCC) epithelial-mesenchymal transition (EMT) model. 28245423 2017
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker disease BEFREE In our previous studies we have shown the inhibitory effects of heparin on Hepatocyte Growth Factor (HGF)-induced invasion and migration in hepatocellular carcinoma (HCC) cells. 27975162 2017